drugset / Trial / NCT00532532

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis

NCT00532532

Phase 2 Terminated 150 enrolled Avigen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity associated with multiple sclerosis. This study has three purposes: 1. To determine whether AV650 is safe for patients with multiple sclerosis; 2. To gather some early evidence as to whether AV650 is effective in treating spasticity in patients with multiple sclerosis; and, 3. To assess what the body does with AV650 once it is ingested (Germany and Czech Republic sites only).

Timeline

Start
2007-09
Primary completion
2008-09
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolperisone Small molecule Oral

Indications

No indication recorded.